

Clinical trials of dabigatran 220mg

TrialResults-center www.trialresultscenter.org

1 thrombosis prevention

Trial	Treatments	Patients	Trials design and methods
dabigatran 220mg vs enoxaparin			
RE-NOVATE 2 <i>unpublished</i> [NCT00657150] n=1010/1003 follow-up: 28-35 days (mean 32d)	dabigatran 220mg once daily for 28-35 Days versus enoxaparin 40mg subcutaneous once daily for 28-35 Days	patients undergoing total hip-replacement surgery	Parallel groups double-blind
RE-NOVATE (220mg) , 2007 [NCT00168818] n=1157/1162 follow-up: 28-35 days, median 33d	dabigatran etexilate 220 mg q.d. for 28-35 days versus Enoxaparin 40 mg q.d. for 23-35 days	Total hip replacement	Parallel groups double blind Europe, Australia, South Africa
dabigatran 220mg vs enoxaparin (europe regimen)			
RE-MODEL (220mg) , 2007 n=694/699 follow-up: 6-10 days, mean 8 days	dabigatran etexilate 220 mg q.d. 6-10 days versus Enoxaparin 40 mg q.d. for 6-10 days	patients undergoing total knee replacement	double blind Europe, Australia, South Africa
dabigatran 220mg vs enoxaparin (US regimen)			
RE-MOBILIZE (220mg) , 2008 n=862/876 follow-up: 12-15 days, median 14d	dabigatran etexilate 220 mg for 12-15 days versus Enoxaparin 30mg SC BID after surgery for 12-15 days	Total knee replacement	Parallel groups double blind US, Canada, Mexico, UK

More details and results :

- antithrombotics for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q37>
- antithrombotics for thrombosis prevention in elective major knee surgery at <http://www.trialresultscenter.org/go-Q38>
- antithrombotics for thrombosis prevention in elective hip replacement at <http://www.trialresultscenter.org/go-Q39>

- anticoagulant for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q184>
- direct antithrombins for thrombosis prevention in all type of patients at <http://www.trialresultscenter.org/go-Q369>
- direct oral anticoagulant (DAO) for thrombosis prevention in all type of patients at <http://www.trialresultscenter.org/go-Q393>
- direct oral anticoagulant (DAO) for thrombosis prevention in elective major knee surgery at <http://www.trialresultscenter.org/go-Q394>
- direct oral anticoagulant (DAO) for thrombosis prevention in elective hip replacement at <http://www.trialresultscenter.org/go-Q395>
- direct oral anticoagulant (DAO) for thrombosis prevention in orthopaedic surgery at <http://www.trialresultscenter.org/go-Q475>

References

RE-NOVATE 2, 0:

unpublished

RE-NOVATE (220mg), 2007:

Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Bller HR Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56 [17869635]

RE-MODEL (220mg), 2007:

Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Klebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Bller HR Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007 Nov;5:2178-85 [17764540]

RE-MOBILIZE (220mg), 2008:

The Oral Thrombin Inhibitor Dabigatran Etexilate vs the North American Enoxaparin Regimen for the Prevention of Venous Thromboembolism after Knee Arthroplasty Surgery. J Arthroplasty 2008;: [18534438]

Entry terms: dabigatran, Pradaxa, Pradax